Related Experiment Video
Updated: May 16, 2026
10:35
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Therapeutic immunomodulation in systemic vasculitis: taking stock.
Xavier Puéchal1, Loïc Guillevin
1Centre de Référence des Maladies Systémiques Auto-Immunes Rares, Vascularites et Sclérodermies Systémiques, Hôpital Cochin, AP-HP, Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. xavier.puechal@cch.aphp.fr
Joint Bone Spine
|December 15, 2012
Summary
This review explores immunomodulation for systemic vasculitides. Rituximab is effective for induction and maintenance in ANCA-associated vasculitis, while other therapies show promise for specific conditions.
Area of Science:
- Immunology
- Rheumatology
- Nephrology
Background:
- Systemic vasculitides encompass a group of rare autoimmune diseases characterized by inflammation of blood vessels.
- Effective treatment relies on immunomodulatory therapies, with ongoing research to refine existing strategies and explore novel agents.
Purpose of the Study:
- To review current data on therapeutic immunomodulation for systemic vasculitides.
- To discuss ongoing and future developments in the treatment of these conditions.
Main Methods:
- Literature review of current data on immunomodulatory treatments for systemic vasculitides.
- Discussion of ongoing and future therapeutic developments.
Main Results:
- Rituximab is a validated induction and maintenance treatment for ANCA-associated vasculitis.
- Plasmapheresis is indicated for severe renal failure and alveolar hemorrhage.
- Mepolizumab shows promise in eosinophilic granulomatosis with polyangiitis.
- Intravenous immunoglobulins are effective in Kawasaki disease.
- Tocilizumab is under investigation for giant-cell arteritis.
Conclusions:
- Immunomodulatory therapies, including rituximab, plasmapheresis, and immunoglobulins, play crucial roles in managing various systemic vasculitides.
- Emerging treatments like mepolizumab and tocilizumab offer new hope for refractory or specific vasculitic conditions.
Related Concept Videos
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inflammatory Response I: Vascular and Cellular
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...